bromodeoxyuridine has been researched along with Cerebral Cortical Dysplasia in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Adams, C; Bonthron, DT; Boycot, KM; Braun, KPJ; Dobyns, WB; Faivre, L; Fry, AE; Giamanco, KA; Gripp, KW; Hevner, RF; Hodge, RD; Johnson, CA; Kholmanskikh, SS; Logan, CV; Majewski, J; Mancini, GM; Mirzaa, G; Pang, K; Parry, DA; Pilz, DT; Rivière, JB; Roberts, N; Ross, ME; Schwartzentruber, J; Sheridan, EG; Singh, S; St-Onge, J; Steinraths, M; Sweeney, E; van Esch, H; Vanstone, M; Verbeek, N; Wieczorek, D | 1 |
1 other study(ies) available for bromodeoxyuridine and Cerebral Cortical Dysplasia
Article | Year |
---|---|
De novo CCND2 mutations leading to stabilization of cyclin D2 cause megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome.
Topics: Abnormalities, Multiple; Animals; Base Sequence; Blotting, Western; Bromodeoxyuridine; Cyclin D2; Electroporation; Exome; Female; HEK293 Cells; Humans; Hydrocephalus; Immunohistochemistry; Malformations of Cortical Development; Megalencephaly; Mice; Microscopy, Fluorescence; Molecular Sequence Data; Mutagenesis, Site-Directed; Polydactyly; Sequence Analysis, DNA; Syndrome | 2014 |